Lenalidomide Olainfarm (Lenalidomide)

The molecule binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex. This binding changes the complex’s substrate profile, leading to degradation of transcription factors such as Ikaros and Aiolos. The downstream effect is modulation of cytokine release, inhibition of new blood‑vessel formation, and activation of immune cells that together trigger apoptosis of malignant cells.

The exact dose is set by the prescribing clinician based on the specific indication, patient weight, renal function, and prior treatment history. Dosing may be adjusted for renal impairment or when combined with other myelosuppressive agents, and the prescriber will follow the relevant clinical guidelines for each disease state.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because of a high risk of fetal harm. Women of child‑bearing potential must use effective contraception, and breastfeeding is not recommended while taking the drug or for a period after the last dose as advised by the prescriber.

To place an order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Lenalidomide belongs to the immunomodulatory imide drug (IMiD) class, sharing a similar mechanism with thalidomide and pomalidomide. Compared with thalidomide, Lenalidomide generally shows higher potency, a more favorable side‑effect profile, and less peripheral neuropathy. Pomalidomide is a newer IMiD often reserved for patients who have progressed after Lenalidomide therapy.

Store the tablets at ambient temperature, preferably below 25 °C, in the original blister pack or container. Protect the product from moisture, direct sunlight, and excessive heat. Do not refrigerate or freeze the tablets, and keep them out of reach of children.

Lenalidomide Olainfarm is taken orally as a whole tablet, usually once daily on a schedule defined by the prescriber. It may be taken with or without food, but patients should follow any specific instructions regarding timing relative to meals or other medications.

The most critical safety concerns include severe neutropenia or thrombocytopenia, which can lead to infection or bleeding, and an increased risk of venous thromboembolism. Additionally, secondary primary malignancies have been reported, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome may occur. Prompt medical attention is required if any of these events arise.

Lenalidomide should not be used by pregnant women or by women who could become pregnant without reliable contraception. Patients with known hypersensitivity to Lenalidomide or any of its excipients should avoid the drug. Caution is also advised for individuals with severe renal impairment, uncontrolled infections, or a history of thromboembolic events unless appropriate prophylaxis is in place.